Intellectual Property - June 1, 2015
Fungal Nail Drug Gets Patent
An improved formulation of Moberg Pharma’s OTC product for the treatment of fungal nails, sold in the U.S. under the Kerasal Nail® brand, recently received a patent from the European Patent Office, according to Moberg. The patent expires in 2034. The corresponding U.S. patent was also granted earlier this spring and Moberg Pharma is pursuing […]
In a new job - November 21, 2014
Moberg Names New U.S. GM
Moberg Pharma AB has appointed Jeff Vernimb as General Manager for its U.S. operations and a member of Moberg’s management team, effective December 15. Vernimb brings to Moberg more than 25 years of experience in consumer health products’ marketing and sales in multi-national and smaller entrepreneurial businesses. Prior to his position with Moberg, Vernimb was vice […]
Acquisition - December 10, 2013
Moberg Pharma acquires OTC brands in the US from Bayer HealthCare
Moberg Pharma has signed a deal to acquire three well established Over-The-Counter brands in the U.S. from Bayer HealthCare, LLC. Total annual sales for the brands are approximately 20 MSEK (ca 3 m$). The purchase price is 32 MSEK (4.8 m$) and is financed by available cash resources. The acquired portfolio includes Domeboro®, a topical […]
